Pricing a specialty therapy isn’t just about numbers; it’s a high-stakes balancing act. Manufacturers must establish pricing that reflects the innovation and value of their therapies while navigating payer pushback, government compliance, and patient affordability....
The Riparian team was proud to participate in this year’s Medicaid Drug Rebate Program (MDRP) Summit, where four of our colleagues joined industry peers to share insights on evolving regulatory and operational challenges....
Stay ahead of the curve on the Medicaid Drug Rebate Program’s Final Rule, which takes effect on November 19, 2024, using our comprehensive white paper packed with valuable insights on what provisions could impact different...
The wave of FDA-approved cell and gene therapies (CGT) is transforming treatment options for diseases that once had few solutions. As more CGTs move from clinical trial to commercial approval and availability, navigating the complexities...
